Updates are available Correction dated 2023-05-13

Article History

Received: 22 February 2022

Accepted: 21 January 2023

First Online: 1 March 2023

Change Date: 13 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10549-023-06928-w

Declarations

:

: M-T.L., A.Y., C.H., P.H., and H.L. report employment at Ambry Genetics, a commercial lab. H.L. reports current employment at Color Health. J.E.G. reports institutional research funding from Myriad Genetics, Ambry Genetics and Invitae Genetics; consulting for Helix Genetics (compensation) and Earli (no compensation); leading two clinical trials for Astra-Zeneca; serving on the scientific advisory board of Konica Minolta (no compensation); conducting a sponsored lecture for Clinical Care Options, LLC; Editorial Services publications, President, Fellows of the AACR Academy, and member, Foundation Board of the American Association for Cancer Research; co-scientific director, Breast Cancer Research Foundation; board of directors, Facing Our Risk of Cancer Empowered; spousal consulting fees from Novartis Oncology, GTx Pharmaceuticals, Aleta BioTherapeutics and H3 Biomedicine, Inc.; a spousal advisory board membership at Oric Pharmaceuticals; and spousal scientific advisory board memberships at Kronos Bio, Susan G. Komen for the Cure, James P. Wilmot Foundation, Inc., Diane Helis Henry Medical Research Foundation, Adrienne Helis Melvin Medical Research Foundation, and Global Biological Standards Institute.

: This study was performed in line with the principles of the Declaration of Helsinki. This study was exempt from review by the Western Institutional Review Board.

: This study was exempt from review by the Western Institutional Review Board.